A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer

Summary

This trial is a registrational Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 combined with Pertuzumab versus docetaxel plus Trastuzumab and Pertuzumab in patients with first-line HER2-positive recurrent or metastatic breast cancer.

Eligibility

Inclusion Criteria:

1. Voluntarily sign the informed consent form and comply with the protocol requirements;
2. Female patients aged ≥18 and ≤75 years at the time of signing the informed consent form;
3. Expected survival time ≥12 weeks;
4. Patients with histologically or cytologically confirmed, previously untreated, unresectable recurrent or metastatic HER2-positive breast cancer;
5. Clear hormone receptor (HR) status;
6. Agree to provide eligible tumor tissue specimens;
7. Have at least one measurable target lesion as defined by RECIST v1.1;
8. ECOG performance status score of 0 or 1;
9. Toxicity from prior anti-tumor therapy must have recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
10. Organ function levels must meet the requirements;
11. For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, with a negative serum pregnancy result, and must be non-lactating; all enrolled patients must use adequate and highly effective contraceptive measures throughout the entire treatment period and for 7 months after treatment completion.

Exclusion Criteria:

1. Received surgical treatment, radical radiotherapy, immunotherapy, etc. within 4 weeks or 5 half-lives prior to the first dose.
2. Previously received ADC drug therapy with camptothecin derivatives as toxins.
3. History of severe cardiovascular or cerebrovascular disease within six months before screening.
4. Concomitant pulmonary disease resulting in severely impaired lung function.
5. History of interstitial lung disease (ILD)/interstitial pneumonia requiring corticosteroid therapy, etc.
6. QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, or frequent and uncontrolled arrhythmias.
7. Diagnosed with another primary malignancy within 5 years before the first dose.
8. Newly developed deep vein thrombosis within 14 days before screening.
9. Hypertension poorly controlled by antihypertensive medications.
10. Patients with active central nervous system metastases.
11. History of severe allergic reactions to recombinant humanized antibodies or any excipient or component of BL-M07D1.
12. History of autologous or allogeneic stem cell transplantation or organ transplantation.
13. Previously received anthracycline therapy exceeding the prescribed dose limit.
14. Positive for human immunodeficiency virus antibody, active hepatitis B virus infection, cirrhosis, or hepatitis C virus infection.
15. Severe infection within 4 weeks prior to the first use of the study drug, etc.
16. Patients with large serous cavity effusions, serous cavity effusions with obvious symptoms, or poorly controlled serous cavity effusions.
17. Receiving systemic corticosteroid therapy \>10 mg/day prednisone or equivalent prior to randomization, etc.
18. Presence of severe neurological or psychiatric disorders.
19. Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks prior to signing informed consent.
20. Intestinal obstruction, Crohn's disease, ulcerative colitis, or chronic diarrhea, etc.
21. Subjects planning to receive or having received live vaccines within 28 days before the first dose.
22. Presence of other serious physical conditions, abnormal laboratory findings, or poor compliance that may increase the risk of participating in the study, interfere with study results, or make the patient unsuitable for participation in the study in the investigator's opinion.

Conditions3

Interventions4

Related trials

• A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors — Sichuan Baili Pharmaceutical Co., Ltd.
• A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors — Sichuan Baili Pharmaceutical Co., Ltd.

Browse More Trials